| Surya Ram Cooper, MD | |
|
100 N Academy Ave, Danville, PA 17822-9800 | |
| (570) 271-6211 | |
| Not Available |
| Full Name | Surya Ram Cooper |
|---|---|
| Gender | Female |
| Speciality | Obstetrics & Gynecology |
| Location | 100 N Academy Ave, Danville, Pennsylvania |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1437491982 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207V00000X | Obstetrics & Gynecology | 287444 (New York) | Primary |
| Entity Name | Trustees Of Columbia University In The City Of New York |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1982993184 PECOS PAC ID: 8527972546 Enrollment ID: O20040407001360 |
News Archive
Houston Methodist neurosurgeons and neuroscientists are looking at a new way to classify pituitary tumors that could lead to more precise and accurate diagnosing for patients in the future.
The use of psychedelics, such as LSD and magic mushrooms, does not increase a person's risk of developing mental health problems, according to an analysis of information from more than 135,000 randomly chosen people, including 19,000 people who had used psychedelics.
SuperGen, Inc., a pharmaceutical company dedicated to the discovery and development of novel cancer therapies, announced that Eisai Inc. today released information regarding a randomized Phase III clinical trial of Dacogen® (decitabine) for Injection in elderly patients with acute myeloid leukemia (AML). The comparator in this trial was low-dose cytarabine, a chemotherapy agent, or supportive care.
Genzyme Corporation announced results today from its CLASSIC I phase 3 trial comparing Clolar® (clofarabine) in combination with the chemotherapy agent cytarabine (ara-c) to cytarabine plus placebo in relapsed-refractory adult acute myeloid leukemia (AML).
› Verified 9 days ago
| Entity Name | Trustees Of Columbia University In The City Of New York |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1508266347 PECOS PAC ID: 8527972546 Enrollment ID: O20151201002613 |
News Archive
Houston Methodist neurosurgeons and neuroscientists are looking at a new way to classify pituitary tumors that could lead to more precise and accurate diagnosing for patients in the future.
The use of psychedelics, such as LSD and magic mushrooms, does not increase a person's risk of developing mental health problems, according to an analysis of information from more than 135,000 randomly chosen people, including 19,000 people who had used psychedelics.
SuperGen, Inc., a pharmaceutical company dedicated to the discovery and development of novel cancer therapies, announced that Eisai Inc. today released information regarding a randomized Phase III clinical trial of Dacogen® (decitabine) for Injection in elderly patients with acute myeloid leukemia (AML). The comparator in this trial was low-dose cytarabine, a chemotherapy agent, or supportive care.
Genzyme Corporation announced results today from its CLASSIC I phase 3 trial comparing Clolar® (clofarabine) in combination with the chemotherapy agent cytarabine (ara-c) to cytarabine plus placebo in relapsed-refractory adult acute myeloid leukemia (AML).
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Surya Ram Cooper, MD 622 W 168th St Ph 16-69, New York, NY 10032-3720 Ph: (212) 305-9368 | Surya Ram Cooper, MD 100 N Academy Ave, Danville, PA 17822-9800 Ph: (570) 271-6211 |
News Archive
Houston Methodist neurosurgeons and neuroscientists are looking at a new way to classify pituitary tumors that could lead to more precise and accurate diagnosing for patients in the future.
The use of psychedelics, such as LSD and magic mushrooms, does not increase a person's risk of developing mental health problems, according to an analysis of information from more than 135,000 randomly chosen people, including 19,000 people who had used psychedelics.
SuperGen, Inc., a pharmaceutical company dedicated to the discovery and development of novel cancer therapies, announced that Eisai Inc. today released information regarding a randomized Phase III clinical trial of Dacogen® (decitabine) for Injection in elderly patients with acute myeloid leukemia (AML). The comparator in this trial was low-dose cytarabine, a chemotherapy agent, or supportive care.
Genzyme Corporation announced results today from its CLASSIC I phase 3 trial comparing Clolar® (clofarabine) in combination with the chemotherapy agent cytarabine (ara-c) to cytarabine plus placebo in relapsed-refractory adult acute myeloid leukemia (AML).
› Verified 9 days ago
Kristin Lorraine Martin, M.D. Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 100 N Academy Ave, Danville, PA 17822 Phone: 570-271-6298 Fax: 570-271-5841 | |
Dr. Latif L. Awad, M.D. Obstetrics & Gynecology Medicare: Not Enrolled in Medicare Practice Location: 100 N Academy Ave, Danville, PA 17822 Phone: 570-271-6298 | |
Dr. Diane De Lisi Timms, DO Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 100 N Academy Ave, Danville, PA 17822 Phone: 570-271-6298 Fax: 570-271-5841 | |
Dr. Brytanie Nicole Marshall, MD Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 100 North Academy Ave., Danville, PA 17822 Phone: 570-271-6298 Fax: 570-271-5841 | |
Dr. Ekaterina Halivelakis, MD Obstetrics & Gynecology Medicare: Medicare Enrolled Practice Location: 100 N Academy Ave, Danville, PA 17822 Phone: 570-271-6211 | |
Dr. Deborah A. Poplawsky, M.D. Obstetrics & Gynecology Medicare: Not Enrolled in Medicare Practice Location: 100 N Academy Ave, Danville, PA 17822 Phone: 570-271-6298 | |
Kajal Angras, DO Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 100 North Academy Ave, Danville, PA 17822 Phone: 570-271-6298 Fax: 570-271-5841 |